# Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases

> **NCT06078813** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cancer Trials Ireland** · enrollment: 126 (estimated)

## Conditions studied

- Solid Tumor Spine Metastases

## Interventions

- **RADIATION:** Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)

## Key facts

- **NCT ID:** NCT06078813
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-21
- **Primary completion:** 2028-08-31
- **Final completion:** 2034-04-01
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06078813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06078813, "Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06078813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*